Ask AI
`Advancing Inflammatory Bowel Disease Management

CE / CME

Advancing Inflammatory Bowel Disease Management With Precision Medicine and Emerging Data

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: May 08, 2025

Expiration: May 07, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jordan E. Axelrad, MD, MPH, FACG, discusses the current prevalence and impact of inflammatory bowel disease (IBD), how to integrate treat to target in your practice, and data on several emerging TL1A inhibitors and the promise they pose in transforming the IBD treatment landscape.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once at the end of the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 28-yr-old man with moderate to severe ulcerative colitis is being managed with a treat-to-target approach. He was recently started on a biologic agent and reports improvement in symptoms over the past 6 wk. His partial Mayo score has decreased, but his HCP is concerned about achieving long-term disease control based on STRIDE-II recommendations. According to treat-to-target strategies in IBD, which of the following biomarkers would be most appropriate to assess objective disease control at this stage of therapy?

A 26-yr-old man with ileocolonic Crohn’s disease is in clinical remission on adalimumab maintenance therapy. At his follow-up visit, he reports no symptoms, and his last colonoscopy 8 mo ago showed mucosal healing. The gastroenterologist is following a treat-to-target strategy and aims to monitor for sustained remission. According to consensus and guideline recommendations, which of the following is the most appropriate monitoring strategy for this patient?

How confident are you in your ability to evaluate and apply emerging clinical evidence supporting TL1A blockade as a therapeutic strategy in IBD?

How many people with inflammatory bowel disease do you provide care for in a typical week?